Preclincial evaluation of gold-DTDTPA nanoparticles as theranostic agents in prostate cancer radiotherapy
OPEN Nanomedicine (London, England) | 28 Jul 2016
KT Butterworth, JR Nicol, M Ghita, S Rosa, P Chaudhary, CK McGarry, HO McCarthy, G Jimenez-Sanchez, R Bazzi, S Roux, O Tillement, JA Coulter and KM Prise
Gold nanoparticles have attracted significant interest in cancer diagnosis and treatment. Herein, we evaluated the theranostic potential of dithiolated diethylenetriamine pentaacetic acid (DTDTPA) conjugated AuNPs (Au@DTDTPA) for CT-contrast enhancement and radiosensitization in prostate cancer.
* Data courtesy of Altmetric.com